Similarly, a comprehensive whole-genome, transcriptome and clinical dataset called the POG570 cohort, had revealed that alterations in EGFR, ADGRG6, and other genes were involved in tumour drug resistance and sensitivity, as well as recurrent noncoding events [50]. Here, EGFR is linked to neoplasm.